side effect

Ilunocitinib, the active ingredient in Zenrelia, is a targeted therapy that provides relief from allergic itching by blocking signals inside immune cells. However, because those same signals are involved in normal body functions, their inhibition can give rise to side effects. Understanding exactly how these effects occur may help owners recognize them early and appreciate why veterinary monitoring matters.

Gastrointestinal Disturbances

The most common side effects reported in clinical trials involved the stomach and intestines, including vomiting, diarrhea, and a drop in appetite. These reactions occur because the Janus kinase enzymes that ilunocitinib inhibits, particularly JAK1, are heavily used by cells lining the gut. Certain cytokines that signal through JAK1, such as interleukin-6 and interleukin-22, help maintain the integrity of the intestinal barrier and regulate local immune responses. When their signaling is dampened, the normal turnover and protection of the gut lining can be disturbed, making the digestive system more sensitive. Additionally, the physical presence of the tablet in the stomach, combined with the rapid onset of local cytokine inhibition, may directly trigger nausea and a reluctance to eat. These effects are often temporary as the body adapts to the medication.

Lethargy

Some dogs appear unusually tired or listless shortly after starting ilunocitinib. The mechanism behind this lethargy is tied to the role of pro-inflammatory cytokines in the brain. Signaling proteins like interleukin-6, which depend on JAK1, communicate with the central nervous system and can influence feelings of fatigue and sickness behavior. By abruptly reducing these signals, the drug may cause a transient state of subdued energy. In some cases, lethargy can also be an indirect consequence of developing anemia or an underlying infection that the medication has partially masked, although many instances resolve without any change in the dosing regimen.

Bone Marrow Suppression and Blood Cell Changes

Ilunocitinib can reduce the production of certain blood cells, a finding serious enough to prompt a boxed warning. The drug’s ability to lower lymphocyte counts is a direct result of how lymphocytes rely on cytokines for their survival. Interleukin-7 and interleukin-15, both of which use JAK1 to transmit their messages, act as growth and maintenance factors for lymphocytes. When these pathways are blocked, the number of lymphocytes circulating in the blood can fall, weakening one arm of the immune defense.

Anemia, or a shortage of red blood cells, has also been observed. The primary signal for red blood cell production, erythropoietin, uses the JAK2 enzyme rather than JAK1. Ilunocitinib was designed to be highly selective for JAK1, but no drug achieves perfect selectivity. At the concentrations reached in a dog’s body, there may be enough spillover inhibition of JAK2 to slightly impair the bone marrow’s response to erythropoietin. Over time, this can reduce the production of new red blood cells and lead to a drop in the packed cell volume. While the drug is not expected to cause a dramatic collapse of the bone marrow, these hematologic effects are the reason veterinarians may recommend periodic blood tests.

Increased Risk of Infections

Because JAK1 is a common gateway for signals that rally the immune system against pathogens, its inhibition weakens several defensive layers simultaneously. Interferons, which are essential for fighting viruses and certain bacteria, signal almost exclusively through JAK1. Multiple interleukins that activate and multiply immune cells also use this kinase. The result is a broad dampening of the host’s ability to detect and eliminate invading organisms. Dogs on ilunocitinib may therefore develop new bacterial skin infections, urinary tract infections, ear infections, or even pneumonia more readily than they otherwise would.

This immune suppression can also permit organisms that normally live harmlessly on the body to proliferate. Demodex mites, which are kept in check by a healthy immune response, can multiply and cause patchy hair loss and scaly skin. Viral papillomas, or warts, may appear more frequently due to reduced antiviral surveillance. Any infection that develops while a dog is on this medication could progress faster and with fewer early warning signs.

Worsening of Cancers

The label for ilunocitinib includes a strict warning against use in dogs with serious infections and a caution that the drug may exacerbate neoplastic conditions. The immune system uses many JAK1-dependent pathways, especially those driven by interferons and interleukin-15, to recognize and destroy abnormal cells before they form tumors. When these pathways are chronically suppressed, pre-existing cancerous cells may face less immune resistance and begin to grow unchecked. This is not to say that ilunocitinib causes cancer, but rather that it can create an environment in which an undiagnosed malignancy finds it easier to advance. For this reason, screening for any hidden disease before starting therapy is an important safety step.

Masking Signs of Illness

One of the more insidious consequences of cytokine inhibition is that the normal flags of sickness can be lowered or eliminated. Fever, for instance, is driven largely by interleukin-6, which signals the brain’s temperature control center through JAK1. By dampening this signal, ilunocitinib can prevent a dog from developing a fever even when bacteria are multiplying in the bladder or deep in the skin. Swelling, redness, and the lethargy that often accompany an infection are also mediated by these same cytokines. A dog could therefore be harboring a serious infection while appearing relatively bright and comfortable. This masking effect makes a veterinarian’s periodic hands-on examinations and laboratory tests far more important than simply watching for symptoms at home.

Potential Long-Term and Theoretical Consequences of Sustained Immune Modulation

Extended use of a JAK1 inhibitor carries theoretical risks that are not yet fully documented in dogs but are understood from the class of medications in general. Continuously lowering lymphocyte numbers over many months could, in theory, leave a dog more vulnerable to opportunistic pathogens that rarely cause disease in a fully immunocompetent animal. Because ilunocitinib can reduce the signaling of several interleukins that help maintain the barrier surfaces of the skin and gut, chronic therapy might also contribute to subtle changes in the microbiome, potentially making the skin or intestines more permissive to yeast or bacterial overgrowth.

The effects of long-term, low-grade JAK2 inhibition on red blood cell and platelet production also remain a theoretical concern with any JAK inhibitor that is not absolutely selective. While ilunocitinib is marketed as a JAK1-selective drug, binding studies show that absolute selectivity is not achieved, and cumulative effects on JAK2-dependent hormonal pathways, including those of growth hormone and prolactin, could manifest in ways not yet captured in six-month safety trials. This is why veterinarians often view treatment as a dynamic process, with the dose and necessity of the drug reassessed over time.

Conclusion

The side effect profile of ilunocitinib is rooted in the very mechanism that makes it effective. By interrupting JAK1-dependent cytokine signals, the drug quiets the vicious itching of allergic dermatitis, but it also disturbs the gastrointestinal lining, lowers lymphocyte counts, impairs defenses against infection, and can unmask or accelerate underlying cancers. Recognizing these effects as logical consequences of cytokine inhibition helps place them in context. They are not random toxicities but predictable outcomes of modulating a pathway that touches many aspects of health. Careful patient selection, adherence to monitoring protocols, and an open line of communication between the pet owner and the veterinarian are the cornerstones of safe use.

Sources

U.S. Food and Drug Administration, Center for Veterinary Medicine. Freedom of Information Summary, NADA 141-586, Zenrelia (ilunocitinib tablets). Approved April 22, 2024. Elanco US Inc. Zenrelia (ilunocitinib tablets) Prescribing Information. 2024. Oclacitinib and other JAK inhibitor prescribing information for comparative mechanism insights: Zoetis Inc. Apoquel (oclacitinib tablet) Prescribing Information. Revised 2023. General pharmacological principles of JAK-STAT pathway and its inhibition are drawn from standard immunological references, including O’Shea et al., “The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention,” Annual Review of Medicine, 2015, and Schwartz et al., “JAK inhibition as a therapeutic strategy for immune and inflammatory diseases,” Nature Reviews Drug Discovery, 2017.

(Source : DeepSeek)

Practical Management of JAK Inhibitors: Before, During, and Special Situations

While understanding the benefits and serious risks of Janus kinase inhibitors is essential, the safe and effective use of these medications also depends on careful planning before the first dose, routine checks during treatment, and knowing how to handle special circumstances like surgery or the need for other medications. These practical steps are a shared responsibility between clinicians and patients, and they help to minimize avoidable harm.

Preparing to Start a JAK Inhibitor

Before a person begins taking a JAK inhibitor, doctors perform a thorough assessment to uncover any hidden infections or conditions that could worsen. This includes screening for tuberculosis using a skin test or a blood test called an interferon-gamma release assay. Because latent tuberculosis can reactivate when the immune system is suppressed, a positive screen usually means treatment for the silent infection must begin before the JAK inhibitor can be started. Screening for hepatitis B and hepatitis C viruses is also standard, as these infections can flare dangerously. Blood tests check the liver, kidneys, and a complete blood count to establish a baseline. The lipid profile is measured because these drugs can raise cholesterol levels. This baseline picture helps separate medication effects from pre-existing problems later on. (...)

Routine Monitoring and Responding to Changes

Once a JAK inhibitor is started, regular laboratory monitoring helps catch problems early. A typical schedule involves checking the complete blood count and liver enzymes every four to eight weeks for the first few months, then every three months once levels are stable. The lipid profile is rechecked about two to three months after starting treatment. If the absolute neutrophil count drops too low, the dose may be reduced or the drug temporarily stopped to protect against infection. A significant drop in hemoglobin or lymphocytes prompts a similar cautious approach. When liver enzyme levels climb more than a modest amount, the medication is usually paused and a search for other causes begins. For elevated cholesterol, lifestyle changes like diet and exercise are encouraged, and a cholesterol-lowering statin medication is often prescribed rather than stopping the JAK inhibitor, if the benefits of the anti-inflammatory treatment remain strong.

Patients are educated to report signs of infection immediately, such as fever, a persistent cough, or burning with urination. They are also taught to recognize the symptoms of a blood clot, including sudden leg swelling, pain, warmth, or sudden chest pain and shortness of breath. Prompt medical attention for these warning signs can be life-saving. Because non-melanoma skin cancers are more common, periodic full-body skin examinations are advisable.

Managing Drug Interactions and Dose Adjustments

JAK inhibitors are processed in the liver by enzymes, primarily those belonging to the cytochrome P450 family, with CYP3A4 playing a major role for drugs like tofacitinib and upadacitinib. When a patient takes a strong inhibitor of this enzyme, such as the antifungal medication ketoconazole or the antibiotic clarithromycin, the level of the JAK inhibitor in the blood can rise significantly, increasing the risk of side effects. In these cases, the dose of the JAK inhibitor is reduced according to the prescribing information. Conversely, strong enzyme inducers like rifampin, used for tuberculosis, can drastically lower the drug level and make it ineffective, so such combinations are generally avoided. Baricitinib and filgotinib are handled more by kidney filtration and other pathways, but they also have specific interaction warnings. All patients should keep an updated list of all medications, including over-the-counter products and supplements, and review it with their prescriber and pharmacist.

Kidney function matters as well, particularly for tofacitinib, baricitinib, and filgotinib, which rely to varying degrees on renal elimination. Doses are lowered for patients with moderate to severe kidney impairment. This is another reason why baseline and periodic kidney function tests are a routine part of care.

Holding Therapy Before Surgery

An operation, especially one that involves a hospital stay or significant immobility, brings together several risks: the stress of surgery, the potential for infection, and the increased chance of blood clots from being still. To lower the risk of serious infection during the vulnerable period around a procedure, JAK inhibitors are temporarily paused. The American College of Rheumatology and other groups recommend holding the medication for a few days before an operation, with the exact number of days based on the specific drug's half-life and how long its biological effect lingers. For most JAK inhibitors, this pause is roughly three to seven days before surgery. The drug is then restarted once the wound is healing well, there are no signs of infection, and the patient is mobile again. This plan must be coordinated between the rheumatologist, dermatologist, or gastroenterologist and the surgical team.

Pregnancy, Breastfeeding, and Fertility

Based on how these drugs work and on animal studies, JAK inhibitors are considered harmful to a developing fetus. They have been associated with pregnancy loss and congenital abnormalities in animal reproduction studies at doses lower than those used in humans. As a result, the prescribing labels strongly advise against their use during pregnancy. Women of childbearing potential are counseled to use effective contraception while taking a JAK inhibitor and for a period of time after the last dose, which varies by drug but can be up to four weeks. If a pregnancy occurs while taking the medication, the patient should contact her healthcare provider promptly to discuss the situation. Whether JAK inhibitors pass into human breast milk is unknown, but because of the potential for serious adverse effects in a nursing infant, breastfeeding is not recommended during treatment and for some time after stopping. There is also a theoretic concern about male-mediated effects, though no specific contraception requirements exist for men. Patient registries collect data on exposures during pregnancy to provide better guidance in the future.

Use in Children

The experience with JAK inhibitors in children is growing but remains limited compared with adults. Tofacitinib is approved for the treatment of polyarticular course juvenile idiopathic arthritis in children aged two years and older, making it one of the few oral targeted options for this young population. The pediatric approval was based on studies showing that the medication reduced joint pain and swelling, with a safety profile broadly similar to that seen in adults, including the risk of infections and laboratory abnormalities. Growth and development are carefully monitored over time. Other JAK inhibitors are being studied in pediatric conditions such as atopic dermatitis and inflammatory bowel disease, but their use in children is mostly off-label outside of clinical trials. The long-term impact of these drugs on a developing immune system remains an active area of investigation, and treatment decisions in children require particularly cautious balancing of potential benefit and unknown long-term risk.

Integrating Practical Care into Daily Life

The integration of JAK inhibitors into routine life goes beyond taking a pill. It involves a structured partnership with a healthcare team, regular blood draws, a commitment to vaccination, and open communication about new symptoms or life changes. For many, the convenience of an oral medication is a significant advantage, but it does not diminish the need for this systematic vigilance. When these practical measures are followed, the window of safety for this powerful class of drugs can be widened meaningfully, allowing patients to derive the maximum anti-inflammatory benefit while keeping foreseeable harms in check.

Sources

Fraenkel L, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care & Research. 2021;73:924-939.
Curtis JR, et al. American College of Rheumatology Guidance for COVID-19 Vaccination in Patients with Rheumatic and Musculoskeletal Diseases. Arthritis & Rheumatology. 2021;73:e60-e75.
Goodman SM, et al. 2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients Undergoing Elective Total Hip or Total Knee Arthroplasty. Arthritis Care & Research. 2022;74:1399-1408.
Pfizer Inc. XELJANZ (tofacitinib) prescribing information. Revised December 2023.
Eli Lilly and Company. OLUMIANT (baricitinib) prescribing information. Revised June 2023.
AbbVie Inc. RINVOQ (upadacitinib) prescribing information. Revised April 2024.
Galapagos NV. JYSELECA (filgotinib) summary of product characteristics. European Medicines Agency. Updated 2023.
Ruperto N, et al. Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 trial. The Lancet. 2021;398:1984-1996.

(Source : DeepSeek)

The Two Faces of Akkermansia muciniphila: How a Gut Bacterium Can Both Protect and Harm

Akkermansia muciniphila has become something of a celebrity in the world of gut health. This bacterium, which naturally lives in the mucus layer lining the human intestine, is commonly described as a next-generation probiotic. Headlines have credited it with helping people stay lean, improving blood sugar control, and even making cancer immunotherapies more effective. Yet a growing body of research, including a striking study from the French National Institute of Health and Medical Research (Inserm), reveals that the same microbe can also be a silent troublemaker. In certain circumstances, Akkermansia muciniphila can trigger autoimmune kidney disease and may contribute to other serious conditions. Understanding this dual nature is not only a story of scientific surprise but also a cautionary tale about the rush to supplement with single gut bacteria.

The reputation of Akkermansia muciniphila as a good bacterium is built on solid evidence. The organism is a specialist that feeds on mucin, the protein-and-sugar gel that coats the intestinal lining. Far from destroying this protective barrier, a healthy population of A. muciniphila actually strengthens it. As the bacterium gently nibbles at the mucus, it sends signals to the cells that produce mucin, prompting them to replenish and thicken the layer. In addition, the breakdown of mucin generates short-chain fatty acids such as propionate and acetate, which nourish the gut wall and reduce inflammation. A landmark human study published in 2019 in Nature Medicine demonstrated these benefits in a clinical setting. Researchers gave a pasteurized form of A. muciniphila to 32 overweight or obese volunteers who had insulin resistance. Over three months, the treatment improved insulin sensitivity, lowered blood markers of inflammation, and decreased body weight compared to a placebo, all without serious side effects. Other research has noted that cancer patients with higher natural levels of A. muciniphila in their gut often respond better to immunotherapy with checkpoint inhibitors. These findings fueled excitement and led to the development of commercial probiotic supplements containing the bacterium.

The darker side of A. muciniphila came into sharp focus in 2023, when Inserm researchers published their work in the journal Science Translational Medicine. The team, led by Renato Monteiro, was investigating IgA nephropathy, also known as Berger’s disease. This autoimmune disorder occurs when abnormal immunoglobulin A antibodies deposit in the kidney’s filtration units, triggering inflammation and gradual loss of kidney function. The cause was long debated, and the gut was suspected to play a role. By analyzing the gut microbiota of patients with IgA nephropathy and comparing them with healthy controls, the scientists found a clear pattern. Patients with the disease had significantly higher levels of A. muciniphila. The connection was not simply one of quantity. The researchers discovered that certain strains of the bacterium produce enzymes capable of snipping off sugars, in particular N-acetylgalactosamine, from the hinge region of IgA1 antibodies. This deglycosylation renders the antibodies unrecognizable to the body’s own machinery, so the immune system treats them as foreign invaders. The resulting immune complexes become trapped in the kidneys, causing the chronic damage seen in Berger’s disease. When the team transplanted the gut microbiota from affected human patients into mice, or colonized mice directly with the harmful strains of A. muciniphila, the animals developed kidney abnormalities mirroring human IgA nephropathy. The work revealed that a bacterium widely hailed as beneficial can, with the right set of enzymes and in the wrong host, spark a devastating autoimmune process.

This is not the only instance where A. muciniphila has been linked to illness. In multiple sclerosis, an autoimmune condition that attacks the central nervous system, several studies have found an overabundance of A. muciniphila in the gut. A study published in 2023 showed that the bacterium could promote the differentiation of pro-inflammatory immune cells called Th17 lymphocytes, which are known drivers of multiple sclerosis. Meanwhile, experiments in mice have indicated that when the mucus layer becomes too thin due to a low-fiber diet, A. muciniphila can overgrow and cling directly to the intestinal lining, further eroding the barrier and causing low-grade inflammation. Other work has revealed that by freeing sugars from mucus, A. muciniphila can inadvertently feed dangerous bacteria like Salmonella, making infections more severe. The microbe that helps maintain gut health can, under the right conditions, undermine it.

The explanation for these contradictory effects lies in a delicate balance described by researchers as the Dr. Jekyll and Mr. Hyde character of A. muciniphila. The microbe’s behavior is highly context-dependent, and three main factors determine whether its role is protective or harmful. The first is strain specificity. Not all A. muciniphila are identical. The harmful deglycosylation enzymes that cause IgA nephropathy are found only in certain genetic variants of the bacterium. Other strains lack these enzymes entirely and may never trigger kidney disease. When people buy a probiotic labeled simply as A. muciniphila, they usually have no information about which strain they are ingesting or how it was selected.

The second factor is abundance. Researchers think there is a narrow Goldilocks zone for this bacterium. A moderate population lives in harmony with the host, stimulating just enough mucin recycling to keep the gut barrier robust. If the population balloons uncontrollably, often as a result of a dietary shift, the rate of mucin consumption can outstrip the gut’s ability to replenish the protective layer. This leads to barrier thinning, bacterial encroachment, and immune activation. A diet lacking in plant fibers, for example, forces the gut’s microbial community to rely more heavily on mucin as an energy source, allowing specialists like A. muciniphila to multiply beyond their normal bounds.

The third factor is host predisposition. A person’s underlying genetic makeup and immune status shape how the body responds to A. muciniphila. Someone with a genetic susceptibility to IgA nephropathy, such as a propensity to produce a certain form of IgA1, may be primed for the harmful deglycosylation cascade. In another individual, the same bacterium may simply support metabolism and barrier integrity without provoking autoimmunity. The state of the rest of the intestinal ecosystem also matters. A. muciniphila is not an isolated player; it interacts with hundreds of other microbial species that can either dampen or amplify its effects.

The practical lesson from all of this is that supplementing with A. muciniphila is not a harmless health hack. The 2019 trial that showed metabolic benefits used a pasteurized, carefully characterized strain at a specific dose, and the participants were screened for health conditions. Unregulated supplements marketed directly to consumers may contain live bacteria of unknown strain identity and potency. In light of the Inserm findings, patients with a personal or family history of kidney disease, or those with any autoimmune condition, should be particularly cautious. The French researchers themselves emphasize that their results should give pause to the idea of widespread, unmonitored A. muciniphila supplementation. They point out that even a bacterium considered an ally can turn into a foe when placed in a body that is not prepared for it.

What remains clear is that A. muciniphila is a central character in the gut’s complex drama. The emerging picture of its double life reframes the way scientists think about probiotics in general. The goal is no longer simply to add “good” bacteria, but to understand which specific microbial strains, in which amounts, and in which people, will promote health rather than disease. For now, the safest way to support a balanced Akkermansia population without risking overgrowth is likely the old-fashioned route. A diet rich in plant fibers, polyphenols from fruits like cranberries and pomegranates, and healthy fats provides a natural environment where this microbe can flourish within its healthy limits. In the gut, as in much of biology, it is all about keeping the scales from tipping too far in either direction.

There are a few additional layers to this story that can deepen the understanding of how a microbe can be both protective and pathogenic, and what that means for the future of gut health.

One important nuance involves the difference between live and pasteurized bacteria. The 2019 human trial that showed metabolic benefits used a pasteurized, or heat-killed, form of Akkermansia muciniphila. Pasteurization deactivates the bacterium so it cannot replicate, colonize the gut permanently, or enzymatically degrade mucus in the same way a live colonizing strain might. This could explain why the trial saw improvements in insulin sensitivity and gut barrier markers without any obvious safety signal. A live, actively dividing strain might, in contrast, have a greater capacity to overgrow and thin the mucus layer in susceptible individuals. This detail matters enormously because many consumer probiotic supplements are marketed simply as Akkermansia and do not clarify whether the bacteria are alive, pasteurized, or even genetically identical to the strain tested in clinical research.

Another angle that has emerged since the Inserm findings is the possibility of screening and selecting safe strains. The French researchers who discovered the link to Berger's disease have proposed that it may be possible to test Akkermansia strains for the specific genes that encode the harmful deglycosylation enzymes. By excluding strains that carry these genes, a probiotic could theoretically be designed to retain the metabolic and barrier-strengthening properties without the risk of triggering autoimmune kidney damage. This idea is still in the research stage, but it illustrates a future where probiotics are not one-size-fits-all products but instead are matched to a person's genetic and immune profile.

The role of diet as a safer alternative to direct supplementation also deserves more attention. Rather than ingesting the microbe itself, it is possible to shift the gut environment to support a healthy, balanced level of Akkermansia naturally. Polyphenols from foods like cranberries, pomegranate, red grapes, and green tea selectively stimulate the growth of the bacterium without overwhelming the system. Prebiotic fibers such as inulin, found in chicory root and onions, can also indirectly boost Akkermansia populations by feeding other bacteria that produce the short-chain fatty acids that Akkermansia thrives on. This dietary approach mimics the ecological conditions under which the microbe normally exists in equilibrium with its host, rather than the brute-force addition of billions of cells through a capsule.

Finally, some of the most recent research is investigating how Akkermansia interacts with the immune system in the brain. A 2024 study using the bacterium in a mouse model of Alzheimer's disease found that while Akkermansia reduced amyloid plaque buildup and tau pathology, it also altered microglial responses in complex ways that were not uniformly beneficial. This reinforces the central lesson that even a single microbe can have body-wide effects that are still poorly understood, and that manipulating it requires more knowledge than simply calling it a good bug or a bad bug. The full picture is one of intense scientific interest, careful optimism, and a strong call for personalized approaches rather than broad population-wide recommendations.

There is more to explore. Recent research from 2025 and 2026 has added even more layers to the Dr. Jekyll and Mr. Hyde story of Akkermansia muciniphila, revealing new contexts where its role is ambiguous, new therapeutic possibilities, and significant developments in the world of probiotics and regulation.

Food Allergy and the Role of Fiber

One of the most striking examples of context-dependence involves food allergies. A 2023 study that continues to influence research into 2025 found that in mice deprived of dietary fiber, a signature change in the gut occurred: the population of Akkermansia muciniphila increased significantly. This was not a good thing. The fiber-deprived mice had a thinner gut mucus barrier, and the overgrowth of the mucin-degrading bacterium led to increased expression of allergy-related immune molecules, a worsened barrier dysfunction, and ultimately an exacerbated allergic reaction to food allergens, including peanut. This demonstrates that the dietary backdrop is critical; when fiber is scarce, the same microbe can tip the immune system toward allergy rather than tolerance.

Parkinson's Disease: Benefits and Cautions

In Parkinson's disease research, the picture has become more nuanced. Some studies have detected that A. muciniphila is actually decreased in the feces of Parkinson's patients. Intervention studies in 2025 showed that administering certain forms of the bacterium could be neuroprotective. One study found that a hypoactive (less metabolically active) strain of A. muciniphila inhibited dopaminergic neuron loss in a mouse model of Parkinson's, reduced neurotoxicity, and induced beneficial microbiota fluctuations. Another 2025 study demonstrated that A. muciniphila ameliorated constipation-depression comorbidity in Parkinson's disease by modulating GDNF signaling, a pathway important for neuron survival.

However, other research has highlighted that the effect is highly dependent on life stage and nutritional context, with the bacterium described as a "double-edged sword" in Parkinson's via the gut-brain axis. This underscores the need for a careful, personalized approach; what is neuroprotective in one scenario could be harmful in another.

Cancer Immunotherapy: Not a Universal Boost

The role of A. muciniphila in cancer immunotherapy response, once thought to be uniformly positive, has also become more nuanced. A 2025 study in non-small-cell lung cancer patients found that while gut enrichment with A. muciniphila was generally associated with better outcomes on immune checkpoint inhibitors, the presence of the bacterium within the tumor itself was a different story. Tumor-associated A. muciniphila was identified as a negative predictive biomarker for immunotherapy efficacy in patients with low PD-L1 expression. A 2026 systematic review and meta-analysis of 16 preclinical studies concluded that the impact of A. muciniphila on cancer outcomes is multifaceted and depends on the specific component used (whole bacterium, extracellular vesicles, or a specific protein called Amuc) and the cancer model. Meanwhile, other 2026 research continues to show that combining A. muciniphila with IL-2-based immunotherapy produces enhanced antitumor immune responses and that the bacterium can reprogram the immunosuppressive tumor microenvironment to sensitize colorectal cancer to anti-PD-1 therapy in a phase I trial. The emerging consensus is that the "where" and "how" matter immensely.

Antibiotic-Induced Mutations and Metabolic Disease

A fascinating 2026 study raised an alarm about how modern medical practices might inadvertently turn A. muciniphila into a foe. Antibiotics can induce mutations in A. muciniphila that promote bacterial survival but compromise its beneficial interactions with the host. This reveals a potential new link between antibiotic-driven microbiome disruption and the global metabolic disease epidemic. The implication is that even if a person carries A. muciniphila, it may be a mutated, less helpful version.

New Health Frontiers: Periodontal Disease and Respiratory Health

Research is expanding into unexpected areas of health. A 2025 study in mice found that A. muciniphila could regulate the gut microenvironment to alleviate periodontal inflammation, suggesting a gut-mouth axis of influence. In the realm of respiratory health, a South Korean company received approval in 2025 for a heat-killed A. muciniphila strain as an individually recognized functional ingredient for improving respiratory health, specifically cough. This marks one of the first government-approved health claims for an Akkermansia product beyond the realm of metabolic health.

The Regulatory Landscape and Consumer Market Evolves

The regulatory landscape has also shifted. In 2025, several A. muciniphila-based ingredients achieved FDA New Dietary Ingredient Notification acknowledgment in the U.S. These products range from postbiotic formulations for metabolic health to heat-killed versions for muscle health and healthy aging. The European Food Safety Authority also issued a safety assessment in 2025 regarding the use of pasteurized A. muciniphila as a novel food.

However, the market remains uneven. In November 2025, the Philippine FDA issued a public health warning against an unregistered Akkermansia dietary supplement, highlighting the ongoing risk of unregulated products and the potential dangers of self-supplementation outside of clinical guidance. The existence of both FDA-acknowledged, clinically tested products and unregistered, potentially unsafe supplements underscores the critical importance of third-party verification and medical supervision for consumers.

Synthesis: Toward a Personalized Future

The fundamental narrative remains one of profound scientific interest combined with caution. The precautionary principle is echoed by a 2025 bibliometric analysis titled "The worldview of Akkermansia muciniphila," which maps the rapid expansion and inherent complexities of research into this organism. The growing understanding is that A. muciniphila is not a simple health hack but a quintessential example of why the future of probiotics must be personalized. The factors of strain specificity, host genetics, dietary context, and ecological balance mean that a web-based probiotic for one person could be a health risk for another. The safest, most evidence-based approach remains supporting a healthy, fiber-rich diet that allows one's native microbial ecosystem to find its own equilibrium, rather than artificially importing a microbe whose full consequences remain an unfolding story.

(Source : Deepseek)

The effects of rapamycin over time and at different doses

Rapamycin, also called sirolimus, does not have one single effect that stays the same in every situation. Its effects depend a lot on how much is taken, how often it is taken, and how long it is used. In approved medical use, it is taken by mouth once a day, with blood levels monitored and doses adjusted when needed. In transplant medicine, it is used to prevent rejection, but the same immune-suppressing action can also raise the risk of infection, reduce vaccine response, slow wound healing, and increase cholesterol, triglycerides, and blood sugar. (FDA Access Data)

At lower or shorter exposure, rapamycin often looks more like a “tuner” than a strong shutoff switch. In animal studies, short-term or intermittent treatment can improve late-life health outcomes, and one intermittent mouse regimen given every five days had a smaller impact on glucose control and the immune system than continuous treatment while still extending lifespan in female mice. A review of newer studies also reports that transient, short-term treatment in early adulthood improved later health in mice, and that brief treatment late in life could improve heart function even after the drug was stopped. (OUP Academic)

That is one reason rapamycin has become interesting in aging research. The idea is not that a little rapamycin is magic, but that brief or intermittent exposure may capture some of the helpful changes seen in animal studies while avoiding part of the long-term downside. Recent reviews of human work say that low-dose intermittent rapamycin has been well tolerated in studies over about a year and has produced only modest changes in aging biomarkers, while the long-term clinical benefit is still not established. Another recent review notes that some early studies suggest short-term rapamycin-like drugs may improve aspects of immune function in older adults. (Frontiers)

The picture changes when exposure becomes longer or the dose is higher. Rapamycin works mainly by blocking mTORC1, but prolonged exposure can also reduce mTORC2 in many cells and tissues. That matters because chronic rapamycin treatment has been linked to glucose intolerance and insulin resistance in animal studies, and the FDA label lists high blood sugar among common side effects. In plain language, the longer the body is exposed, the more likely rapamycin is to start affecting pathways that help keep metabolism balanced, not just pathways tied to growth and immune activation. (PubMed)

Dose also matters in a very practical way. In the FDA label, 2 mg/day had a better safety profile than 5 mg/day in renal transplant studies, and the label explicitly warns that higher doses can bring dose-dependent adverse events. That does not mean the lower dose is harmless; it means higher doses tend to make side effects more likely. The same label also shows that both 2 mg/day and 5 mg/day can reduce rejection risk, which is a good example of how the same drug can be effective at more than one dose but less tolerable at the higher one. (FDA Access Data)

Some of the bad effects become more common with ongoing use because the immune system stays damped down for longer. The FDA and MedlinePlus warn about serious infections, less effective live vaccines, skin cancer risk, poor wound healing, swelling, diarrhea, and other common problems. Rapamycin can also cause mouth sores, and a 2024 study on off-label use reported that low-dose users could still develop mild aphthous-like ulcers. So even when the dose is not high, the body can still show visible signs that repair and immune balance are being altered. (MedlinePlus)

The main reason the pattern changes over time is that rapamycin’s biology is not static. Early on, the drug mostly blocks mTORC1, which slows cell growth and immune-cell expansion. With longer exposure, more evidence points to additional effects on mTORC2, which helps explain why chronic treatment is more likely to disturb glucose handling and other metabolic functions. In this sense, short-term use is more likely to give a narrowed effect, while long-term use is more likely to spread into broader systems such as metabolism, tissue repair, and immune defense. That does not make long-term use “bad” in every setting, but it does mean the trade-off gets larger over time. (PubMed)

The overall lesson is simple: with rapamycin, timing and dose change the story. Short or intermittent use can sometimes preserve some helpful effects, especially in animal studies, while causing fewer immune and metabolic problems than continuous exposure. Higher doses and longer exposure make side effects more likely, especially infection risk, wound-healing problems, blood sugar changes, and lipid changes. That is why rapamycin is best understood not as a single yes-or-no drug, but as a powerful pathway drug whose effects depend heavily on how it is used. (OUP Academic)

(Source : ChatGPT)

Why Retinoids Cause Side Effects: A Clear Overview

Here’s a clear, plain-language explanation of why retinoids (like all-trans retinoic acid, isotretinoin, or synthetic drugs such as bexarotene) can cause the particular risks you asked about. I’ll explain the underlying reasons without technical clutter, so the picture feels intuitive.

Retinoids are powerful because they change how cells read their genes. They slip into receptor “switches” inside the cell’s control center and turn on or off whole programs of behaviour. That ability to push immature or diseased cells to “grow up” or to change how they behave is exactly why retinoids can help in some cancers. But the same force that reprograms cells can also upset the balance of tissues and organs — and that’s how side effects arise. (NCBI)

Take differentiation syndrome, for example. In some leukemias, retinoids cause a wave of immature cancer cells to rapidly mature. Those newly maturing cells start producing inflammatory signals and surface proteins that make them stick to blood vessel walls and move into tissues (the lungs are a common target). The result is a sudden, widespread inflammatory reaction and fluid leaking from vessels into organs: patients can get fever, trouble breathing, weight gain from fluid, low blood pressure, and organ strain. In short, a treatment that forces a lot of abnormal cells to change at once can produce a dangerous inflammatory flood — which is why doctors watch for it closely and treat it fast (often with steroids). (PMC)

Liver problems happen for two related reasons. First, most retinoids are handled and broken down by the liver, so high doses or long use put metabolic stress on liver cells. Second, because retinoids change gene activity broadly, they can alter liver metabolism in ways that show up as abnormal liver blood tests, and in rare cases more serious liver injury. That combination — direct metabolic load plus changes in gene programs that control liver function — explains why liver tests are monitored when people take these drugs. (NCBI)

The changes in blood fats (cholesterol and triglycerides) are another example of gene-level effects creating a metabolic problem. Some retinoids, especially drugs that target the RXR family of receptors (bexarotene is a well-known example), increase the production of molecules that slow the normal breakdown of triglycerides and shift how the liver handles lipids. Clinically this often shows up quickly as big rises in triglycerides and changes in cholesterol — sometimes severe enough to need drug dose changes or cholesterol-lowering medicines. So the same gene-switching power that helps cells can also nudge the body’s fat-handling system into an unhealthy state. (PMC)

Teratogenicity — the very high risk of birth defects — stems from a different but conceptually similar fact: retinoic acid is a natural signalling molecule that tells an embryo how to form its head, heart, limbs and brain. Those signals must be present at the right place and right amount during development. Giving extra retinoids disturbs those precise patterns, changing which developmental genes are on or off at the wrong times. That disruption can cause characteristic defects in the face, heart, central nervous system and other organs. Because these effects are direct, powerful, and often permanent, retinoid drugs are strongly avoided in pregnancy and require strict pregnancy prevention measures when prescribed. (PMC)

Finally, a few practical consequences follow from these mechanisms. Because retinoids act on many tissues via gene regulation and because their breakdown and side effects involve organs like the liver and the blood vessels, doctors monitor blood tests (liver, lipids), watch for early signs of differentiation syndrome, advise strict pregnancy prevention, and sometimes give preventative treatments (for example, steroids to blunt inflammation if differentiation syndrome is suspected). Many side effects are manageable if caught early, but some can be serious if missed — which is why medical supervision is essential. (ASH Publications)

(Source : ChatGPT)

Methotrexate can cause a range of side effects because of how it interferes with cell growth and with the body’s use of folate (a vitamin needed to make DNA and new blood cells). At the heart of the drug’s action is inhibition of enzymes involved in folate and nucleotide synthesis, so tissues that normally turn over rapidly — like the lining of the gut, hair follicles, and bone marrow — are the ones most likely to be affected. This basic biochemical effect helps explain many of the common side effects. (CNIB)

Because the bone marrow makes red blood cells, white blood cells and platelets, methotrexate’s interference with cell division can reduce those cell lines. That may lead to anaemia (tiredness and shortness of breath), low white cell counts (higher infection risk), or low platelets (easy bruising or bleeding). These risks are why doctors check blood counts regularly while someone is taking methotrexate. (FDA Access Data)

The drug also commonly irritates tissues with fast cell turnover, which explains symptoms like nausea, poor appetite, and mouth sores (stomatitis). The gut lining renews itself quickly, so blocking nucleotide synthesis there produces these gastrointestinal side effects more readily than in slower-turnover tissues. Some gastrointestinal injury from methotrexate also appears to involve oxidative and inflammatory processes in the gut. (MDPI)

Liver effects are another important concern. Methotrexate can raise liver enzymes and, in some people over long periods or at higher cumulative doses, contribute to more serious liver damage. The exact reasons include effects related to folate metabolism and other drug-related stresses on liver cells; this is why liver blood tests are part of routine monitoring and why alcohol use is usually discouraged. (CNIB)

There is also a less common but serious lung reaction called methotrexate-induced pneumonitis. This is believed to be an immune-mediated or hypersensitivity-type reaction in many cases and can cause cough, breathlessness and fever; it can occur even at low doses and usually prompts immediate stopping of the drug. Because it can be unpredictable, people are advised to report new respiratory symptoms quickly. (MedlinePlus)

Other effects flow from the drug’s impact on rapidly dividing cells or from idiosyncratic immune reactions: hair thinning (because hair-matrix cells divide rapidly), mouth and skin sensitivity, rare severe skin reactions, and, at higher doses or with certain routes of administration, neurological effects. Methotrexate is also teratogenic — it can harm a developing fetus — because folate-dependent processes are crucial during embryonic development, so it is contraindicated in pregnancy and requires reliable contraception around treatment. (Drugs.com)

Fortunately, some side effects are reduced by simple measures. Giving folic acid (or folinic acid) alongside methotrexate replaces some of the folate pathways the drug blocks and has been shown in trials and reviews to lower rates of nausea, mouth sores and abnormal liver tests, and to help people tolerate the drug better. Regular blood tests, liver checks, avoiding excessive alcohol, and prompt reporting of symptoms (especially cough or signs of infection) are standard risk-reduction steps. (Cochrane)

In short, methotrexate’s side effects are largely downstream consequences of its core biochemical action — blocking folate-dependent cell processes — combined with some immune-mediated reactions. Because the risks can be serious but are generally manageable with monitoring and folate supplementation, clinicians balance the benefits and harms and tailor monitoring and dosing to keep treatment safe. (CNIB)

(Source : ChatGPT)

It’s confusing because the same family of chemicals — anthraquinones — can look helpful in one kind of study and worrying in another. In simple terms, some anthraquinone compounds (especially when used repeatedly over a long time as stimulant laxatives or when present in poorly processed botanical products) have shown signs that they could raise cancer risk, while other anthraquinones (and related drugs) kill cancer cells in laboratory tests. The difference comes down to dose, how they’re used, and what kind of evidence we’re looking at. The European Food Safety Authority reviewed the science and concluded that hydroxy-anthracene derivatives (a subgroup of anthraquinones) should be regarded as genotoxic and potentially carcinogenic unless there are specific data showing otherwise. That is why regulators have warned against their long-term use in foods or supplements. (European Food Safety Authority)

How could an anthraquinone cause cancer? There are two main biological ideas scientists use to explain the concern. One is direct DNA damage — some anthraquinones or their metabolites can damage DNA or cause mutations in cells (this is called genotoxicity). If DNA damage is frequent and not repaired, those mutations can accumulate and eventually help a cell turn cancerous. Laboratory tests and some toxicology reports have found genotoxic signals for certain compounds, which is why bodies such as EFSA treat the group cautiously. (MDPI)

The other mechanism is chronic irritation and increased cell turnover in the lining of the large intestine. Anthraquinone laxatives work by irritating the colon and increasing fluid secretion and muscle contractions so stool moves faster. With long, repeated exposure that irritation can cause many colon cells to die and be replaced repeatedly. High rates of cell death and regeneration increase the chance that DNA copying errors will slip through and lead to abnormal growth. In animals, whole-leaf Aloe preparations and some individual anthraquinones produced intestinal hyperplasia and tumors in long feeding studies, which supports the biological plausibility of the risk. (PMC)

What does human research say? The human evidence is mixed and not definitive. Large reviews and meta-analyses of observational studies show a weak trend toward higher colorectal cancer with long-term anthraquinone laxative use, but the results are inconsistent and not always statistically conclusive; study quality and the possibility of other explanations (for example, people who take laxatives long-term may have different diets, medical conditions, or other risk factors) make firm conclusions difficult. Because the studies are mainly observational, they can suggest a possible link but can’t prove cause and effect. Still, regulators and many toxicologists treat the combination of animal data, lab genotoxicity signals, and suggestive human studies as enough reason to advise caution. (PubMed)

Not all anthraquinones are equal. Some specific compounds have stronger evidence of harm. Danthron (also called chrysazin) has been judged by expert panels and listed in carcinogen reports based on animal cancer studies. Other anthraquinones such as emodin or aloe-emodin have shown mixed results in genotoxicity testing — some studies raise worries, others do not — so regulators have treated the whole group cautiously unless compound-specific safety data exist. That’s why authorities have restricted or advised limits on certain aloe and anthraquinone preparations in foods and supplements. (NCBI)

What does this mean for you in practice? The sensible takeaway is short and practical: occasional, short courses of anthraquinone laxatives (as traditionally used for brief relief of constipation) are different from chronic, unsupervised daily use. Because of the unresolved safety questions, experts recommend avoiding long-term self-treatment with anthraquinone-containing laxatives or supplements, using gentler alternatives for chronic constipation (fiber, fluids, lifestyle changes, or doctor-recommended osmotic laxatives), and discussing any prolonged use with a healthcare professional. If you’re concerned about a particular product (for example, whole-leaf aloe supplements or long-used herbal laxatives), check whether the manufacturer measures and limits hydroxy-anthracene content and consider safer options. (European Food Safety Authority)

(Source : ChatGPT)

Topical steroid withdrawal happens when skin that has been exposed to regular, often high-potency steroid creams for weeks to months reacts badly after the medicine is stopped. Instead of simply returning to the baseline rash, the skin can turn intensely red, burn, itch, peel, swell, and sometimes weep. This pattern of symptoms is what patients and many clinicians call topical steroid withdrawal (also called red skin syndrome). The condition is increasingly reported, but how often it happens and exactly why it happens are still being studied. (NCBI)

One simple way to understand the basic biology is to think about what steroids do to normal skin. Topical corticosteroids narrow (constrict) the tiny blood vessels in the skin and strongly suppress local inflammation and immune activity. When the steroid is stopped after long or heavy use, those blood vessels can rebound — they widen quickly and excessively — which causes the sudden, bright redness and a burning feeling. Research points to increased release of nitric oxide and other signals that drive this rebound vasodilation as an important part of the picture. (DermNet®)

Another key mechanism involves changes inside the skin’s cells. Steroids act through glucocorticoid receptors to change which genes are switched on or off. Prolonged steroid exposure can alter receptor levels and behaviour, and it may suppress the skin’s own ability to make cortisol locally. When the external steroid is removed, the cells are left out of balance: normal control systems are damped or dysregulated, and inflammatory pathways can surge back in a disordered way. This receptor and cellular dysregulation is one reason the rebound is often more severe or differently patterned than the original rash. (Springer Nature)

Long steroid use also damages the skin barrier and the local ecosystem. Repeated application thins the skin, impairs normal repair, and changes the microbiome (the mix of bacteria and other microbes on the skin). Those changes make the skin more prone to irritation, infection, and prolonged inflammation once steroids stop. Some recent studies also suggest deeper metabolic effects — for example, shifts in lipids and mitochondrial function — that may help explain why recovery can be slow and why symptoms sometimes include widespread sensitivity, sweating, or other systemic complaints. But these newer ideas are still under investigation. (PMC)

Who is most likely to get withdrawal and how long it lasts depends on several things: the steroid’s strength, how often and how long it was used, where on the body it was applied (areas like the face and scrotum are especially vulnerable), and individual sensitivity. For some people the worst symptoms begin within days to weeks of stopping; for others recovery can take many months or even years. Because research is ongoing, clinicians don’t all agree on diagnostic criteria or the best treatment, and some experts caution that not every red rash after stopping steroids is TSW — distinguishing it from a flare of the original disease can be hard. (NCBI)

In plain terms: topical steroid withdrawal appears to be a mix of rebound blood-vessel overreaction, disturbed steroid signalling inside skin cells, and a damaged skin barrier and microbiome — all of which combine to produce intense, often long-lasting symptoms after stopping prolonged topical steroid use. Because the science is still developing and management can be complicated, anyone who suspects they have TSW should discuss it with a dermatologist so they can get an accurate diagnosis and a safe plan for recovery. (journals.sagepub.com)

Topical steroid withdrawal is mainly associated with topical (skin-applied) corticosteroids.

Oral (pill) or intravenous corticosteroids can cause systemic withdrawal if stopped suddenly after long use (due to adrenal suppression), but they do not cause topical steroid withdrawal of the skin in the same way. The skin-specific rebound reactions seen in TSW are linked to long-term local steroid exposure and its effects on skin blood vessels, receptors, and barrier function.

(Source : ChatGPT)

Corticosteroids can affect the eye in two main, clinically important ways: they can make the lens cloudy (a cataract), especially a type called a posterior subcapsular cataract, and they can raise the pressure inside the eye (ocular hypertension), which — if it lasts — can damage the optic nerve and cause glaucoma. These effects are well described and can occur after many kinds of steroid use: eyedrops, injections around or into the eye, pills, and even high-dose inhaled or injected steroids. (CNIB)

Why cataracts happen is not completely nailed down, but the simplest way to think about it is that steroids change how lens cells behave and how lens proteins are maintained. The lens is a transparent, tightly organised structure that depends on precise protein chemistry and active maintenance by lens epithelial cells. Steroids interact with receptors in these cells and can alter gene activity, protein processing, and the balance of growth factors and antioxidants in the eye. Over time those changes can produce abnormal protein clumping or cell changes in the rear part of the lens, leading to the typical “posterior subcapsular” clouding seen with steroid-related cataracts. Because the exact chain of events is complex, scientists describe several possible mechanisms rather than one single cause. (PubMed)

The way steroids raise eye pressure is better understood. Fluid inside the front of the eye is normally drained through a sponge-like structure called the trabecular meshwork. Steroids change the behavior of the cells in that meshwork: they change the proteins those cells make, encourage accumulation of extracellular material, alter the cell skeleton, and can increase expression of particular proteins linked to impaired drainage. When outflow is reduced, the fluid builds up and intraocular pressure (IOP) rises. Some people are genetically or biologically more sensitive to this effect and respond with large pressure rises, while others have only small changes. Prolonged high pressure can damage the optic nerve and produce glaucoma. (PMC)

Who is most at risk, and how fast it happens, depends on several things: the strength and form of the steroid, how it is given, the dose and duration, and individual susceptibility. Potent topical eye steroids, injections into or near the eye, and prolonged high-dose oral or injected steroids carry higher risk than short courses or low-dose inhaled/nasal steroids (though even inhaled steroids at high doses have been linked to pressure rises). People with a personal or family history of glaucoma, very nearsighted people, children, and people with certain systemic conditions can be more likely to develop a significant pressure rise. Cataracts from steroids typically develop over months to years of exposure, while pressure rises can sometimes be seen within weeks to months and occasionally even sooner after an intraocular steroid injection. (Moran CORE)

The good news is that many pressure rises are detectable and manageable if patients are monitored. Eye pressure often falls back toward normal after the steroid is stopped, and pressure-lowering eye drops — or in persistent cases laser or surgery — can control IOP. Cataracts, however, do not reverse when the steroid is stopped; they may progress and eventually need cataract surgery to restore clear vision. Because early pressure rises usually cause no symptoms, clinicians advise a baseline eye check before or soon after starting long-term or high-dose steroid therapy and repeated checks while treatment continues; intravitreal steroid implants or injections often have specific schedules for IOP checks (for example at 1 week, then 2 weeks, then monthly for several months) because of the known risk pattern. Stopping or switching to less-potent or shorter-acting steroid preparations, using steroid-sparing alternatives when possible, and choosing agents designed to lower ocular side effects can all reduce risk. (Glaucoma Today)

In plain terms: corticosteroids can change cell behaviour in the lens and the drainage channels of the eye. Those changes cause the lens to become cloudy over time and can block fluid outflow, raising pressure quickly in some people. That’s why doctors try to use the lowest effective steroid dose for the shortest time, choose the safest formulation when the eye is at risk, and check eye pressure and vision at appropriate intervals while someone is on ongoing steroid therapy. If you or someone you care for is prescribed repeated or strong steroids, mention eye checks to the prescriber and consider a referral to an eye specialist for baseline and follow-up exams. (CNIB)

(Source : ChatGPT)

Corticosteroids can cause side effects because they act like powerful versions of the body’s natural stress hormone and change how many cells in the body behave. When you take a corticosteroid pill, get an injection, or use a high-dose inhaler, the drug reaches many tissues and fits into “glucocorticoid” receptors inside cells. Once the drug is inside a cell and attached to that receptor, it moves into the cell’s control center (the nucleus) and changes which genes are turned on or off. Those gene changes reduce inflammation and calm the immune system, which is why corticosteroids are so effective — but the same gene changes also alter normal processes such as how the body handles sugar, protein, fat, salt, and bone, and that leads to side effects.

One common pathway to side effects is immune suppression. By turning down immune activity, corticosteroids make it easier to control autoimmune inflammation or allergic reactions, but they also make it easier for infections to take hold or to become more severe. That is why people on higher doses or long courses of steroids have a higher risk of infections and why doctors watch for signs of illness while someone is taking them.

Corticosteroids also change metabolism. They increase the liver’s production of glucose and reduce the way muscles and fat use that glucose. The result can be higher blood sugar levels, which may cause existing diabetes to worsen or, in some people on long-term therapy, contribute to new-onset diabetes. At the same time, steroids increase appetite and redistribute fat in the body, which can lead to weight gain and the characteristic “moon face” or central fat accumulation seen with prolonged high-dose therapy.

Fluid balance and blood pressure can be affected because some corticosteroids have effects similar to another natural hormone that controls salt and water. That can cause the body to retain salt and water, leading to swelling, higher blood pressure, and changes in potassium levels. The exact degree of this effect depends on which steroid is used and at what dose.

Bones and muscles are vulnerable to the gene-level effects of corticosteroids. Steroids reduce bone formation and increase bone breakdown, lowering bone density over time and raising the risk of fractures. They also encourage the breakdown of muscle protein, which can cause weakness and make it harder to recover from illness or stay active. Skin becomes thinner and more fragile because steroids interfere with the normal production of collagen and skin repair.

Eyes and other organs can be affected too. Long-term steroid use increases the risk of cataracts (clouding of the lens) and high pressure inside the eye (glaucoma). The gut lining may be more prone to irritation, and wounds can heal more slowly because the normal inflammatory steps that help repair tissue are suppressed.

One especially important effect relates to the body’s own steroid production. When someone takes corticosteroids for more than a short period, the adrenal glands reduce their own output of natural cortisol because the body senses the drug is providing enough steroid. If the prescribed drug is stopped suddenly, the body may not be able to produce cortisol fast enough, and the person can develop adrenal insufficiency — a dangerous condition that causes weakness, low blood pressure, and fainting. That is why long courses are usually tapered rather than stopped abruptly.

How likely and how severe these side effects are depends on the dose, how long the drug is used, and the route of administration. Short courses at moderate doses commonly produce temporary effects like mood changes, increased appetite, or a temporary rise in blood sugar, whereas chronic high-dose treatment is much more likely to cause long-term problems such as bone loss, muscle wasting, or adrenal suppression. Local treatments (for example, creams, eye drops, or low-dose inhalers) generally cause fewer whole-body effects because less drug reaches the circulation, but repeated or high-strength local use can still cause systemic problems.

In plain terms, corticosteroids trade powerful, rapid control of inflammation and immune activity for a higher chance of upsetting other body systems. That trade-off is often worth it medically, but it requires careful dosing, the shortest effective duration, and close monitoring by a clinician so that benefits outweigh harms. If you or someone you care for is prescribed corticosteroids, it’s sensible to ask the prescriber which specific side effects to expect, how they will be monitored, and what measures (like bone protection, blood-sugar checks, or a gradual taper) will be put in place.

(Source : ChatGPT)